The core claim—that Tango Therapeutics reported durable responses in the large majority of pancreatic cancer patients receiving the vopimetostat-daraxonrasib combination in an early-stage trial—is directly confirmed by Tango's own press release dated June 8, 2026, distributed via GlobeNewsWire. The company reported a 92% objective response rate (11 out of 12 evaluable PDAC patients) and a 90% 6-month progression-free survival rate, with no discontinuations due to adverse events. The STAT News article from the same date, authored by Andrew Joseph, mirrors these details, describing the results as showing "durable responses in the large majority of pancreatic cancer patients who received both medicines."
It is worth noting that the trial is still ongoing and the data comes from a relatively small cohort—12 evaluable PDAC patients in the daraxonrasib arm, with a data cutoff of May 28, 2026. Tango's CEO called the results "extremely encouraging" and announced plans to advance the combination into Phase 3 development. An independent oncologist from Dana-Farber Cancer Institute also commented positively on the data. However, these are early-stage results from a Phase 1/2 trial, and the small sample size means the findings, while promising, are preliminary. The claim as stated accurately reflects what Tango reported.
The claim is directly supported by Tango Therapeutics' own press release dated June 8, 2026, which provides specific clinical data (92% ORR, 90% 6-month PFS rate) from the Phase 1/2 trial. The STAT News article from the same date corroborates the announcement. The evidence is primary-source material from the company itself, with specific patient numbers and data cutoff dates, making it strong for verifying what Tango reported.
